Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "PAS"

920 News Found

Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024
Biotech | September 25, 2024

Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024

These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity


DevCo completes strategic capital raise for investment in Medix Biochemica
News | September 23, 2024

DevCo completes strategic capital raise for investment in Medix Biochemica

The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives


Ind Swift Laboratories opens marketing office in New Delhi
News | September 23, 2024

Ind Swift Laboratories opens marketing office in New Delhi

This office will be the central hub for all operations related to companies ethical pharmaceutical business


Aster DM Healthcare to launch the Rs. 220 crore Women & Children’s Hospital in Hyderabad
Healthcare | September 22, 2024

Aster DM Healthcare to launch the Rs. 220 crore Women & Children’s Hospital in Hyderabad

The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care


Suven Pharmaceuticals names Vivek Sharma as Executive Chairman
People | September 20, 2024

Suven Pharmaceuticals names Vivek Sharma as Executive Chairman

Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform


GPCB issues directive for closure of Tatva Chintan Pharma Chem Ankleshwar plant
Policy | September 14, 2024

GPCB issues directive for closure of Tatva Chintan Pharma Chem Ankleshwar plant

GPCB has also asked to submit a bank guarantee of Rs. 2, 00,000 for compliance assurance at the time of revocation and has also ordered to deposit interim environment damage compensation amount


Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial
Clinical Trials | September 10, 2024

Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population


Briefs: Wanbury and Bafna Pharmaceuticals
News | September 10, 2024

Briefs: Wanbury and Bafna Pharmaceuticals

Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API


Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform
News | September 10, 2024

Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform

Agreement further expands Aptar Pharma’s leading respiratory portfolio


Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg
Drug Approval | September 06, 2024

Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug